ArticleClinical and translational science2025
Methods of Estimating Plasma Pharmacokinetics From Minimally Invasive, High Temporal Resolution Measurements of Interstitial Fluid Drug Concentrations.
Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances and Challenges in Wearable Sensors for Health Monitoring.ACS applied materials & interfaces · 2026Review
- A Minimally Invasive, Subcutaneous Biosensor Reliably Estimates Plasma Methotrexate Exposure and Quantifies Plasma-to-Tissue Transport Kinetics.ACS pharmacology & translational science · 2026Article
- Continuous, Week-Long, Seconds-ResolvedJournal of the American Chemical Society · 2026Article
- Methods of Estimating Plasma Pharmacokinetics From Minimally Invasive, High Temporal Resolution Measurements of Interstitial Fluid Drug Concentrations.Clinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In therapeutic drug monitoring, plasma drug concentrations are used to guide dosing decisions, significantly improving outcomes for many therapeutic interventions. Due to the cumbersome, laboratory-based approaches used to measure such drug concentrations, however, such monitoring is slow to return actionable information to the clinician and is performed far less frequently than would be optimal. In response, approaches are being developed by which in vivo drug concentrations can be monitored in real time and at high frequency in the subcutaneous or intradermal interstitial fluid-measurements that are safe, convenient, and minimally invasive. In the furtherance of this approach, here, we explore theoretically the ability to use such high-frequency sub- or intradermal measurements to estimate the corresponding plasma concentration-time courses, as the latter remain the basis of effectively all clinical decision making. Doing so, we find that, given various physiologically and technologically plausible assumptions, it is possible to accurately estimate plasma concentration-time courses from measurements of interstitial fluid taken at two nonredundant sites in the interstitial fluid. This ability to derive clinically important plasma pharmacokinetics using minimally invasive subcutaneous or intradermal sensor placements has the potential to significantly improve the precision and reach of therapeutic drug monitoring and, with that, the safety and efficacy of drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.